Management of Anti-Tubercular Drugs in Liver Disease

Risk Assessment and Considerations

Tuberculosis treatment in patients with preexisting liver disease poses significant challenges due to increased risk of drug-induced liver injury (DILI) and potentially life-threatening consequences in those with marginal hepatic reserve 1
Baseline liver function abnormalities may be due to TB itself, which typically improve with effective treatment 2

Standard regimen with close monitoring: INH, RIF, PZA, and EMB for 2 months, followed by INH and RIF for 4 months, as recommended by the Infectious Diseases Society of America 1, 3
For moderate to advanced liver disease, treatment without PZA is preferred: INH, RIF, and EMB for 2 months, followed by INH and RIF for 7 months (total 9 months), as suggested by the American Thoracic Society 1, 2
For patients with advanced liver disease, a regimen with minimal hepatotoxicity may be used: RIF and EMB with a fluoroquinolone, injectable agent, or cycloserine for 12–18 months, as recommended by the Infectious Diseases Society of America 1, 3

Patients with known chronic liver disease should be monitored weekly for two weeks, then biweekly for the first two months, then monthly, according to the British Thoracic Society 4
If ALT/AST increases to five times normal or bilirubin increases, discontinue RIF, INH, and PZA immediately, as advised by the British Thoracic Society 4

After normalization of liver function, drugs can be reintroduced sequentially with careful monitoring, as recommended by the British Thoracic Society 4

Expert consultation is strongly advised when treating TB in patients with advanced or unstable liver disease, as suggested by the American Thoracic Society and the Infectious Diseases Society of America 2, 3
The crucial efficacy of INH and particularly RIF warrant their use and retention if at all possible, even with preexisting liver disease, according to the Infectious Diseases Society of America 1, 3